Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Returns
Return on equity-38.1%-7.9pp-34.2%+0.2pp-30%+1.9pp-27.4%+0.8pp-30.3%-5.8pp
Return on assets-36.2%-7.2pp-32.3%+0.1pp-28.7%+1.5pp-26.3%+0.6pp-29%-5.5pp
Return on invested capital-47.1%-9.0pp-43.1%+5.0pp-37.5%+3.9pp-34.2%+1.8pp-38%-7.0pp
Liquidity
Current ratio22.6×+1.6×19.9×-0.1×26.5×+0.2×28.9×-1.4×21×-16.1×
Quick ratio22.6×+1.6×19.9×-0.1×26.5×+0.2×28.9×-1.4×21×-16.1×
Cash ratio1.5×-0.9×2.2×+0.5×2.1×-0.2×2.1×-0.5×2.4×+0.3×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Per Share
Book value per share$4.60+1.9%$5.07+2.1%$5.30+1.6%$5.61+2.8%$4.52-26.1%
Valuation
Market capitalization$3.38B+61.3%$2.63B+3.9%$1.71B-31.8%$1.55B-7.9%$2.09B+31.1%
Enterprise value$3.35B+63.5%$2.57B+3.2%$1.67B-32.3%$1.51B-8.1%$2.05B+30.3%
Price / book6.9×+2.0×-0.5×3.1×-2.1×2.6×-0.7×4.9×+1.9×
Free cash flow yield-4.4%+1.3pp-5.5%-1.1pp-7.8%-3.4pp-8.1%-1.9pp-5.7%+0.5pp
Earnings yield-5.2%+1.8pp-6.4%-1.1pp-9.2%-4.2pp-9.7%-2.8pp-7%-0.3pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Edgewise Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Edgewise Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.